InsiderSignal.AI

InsiderSignal.ai

BCAX - Bicara Therapeutics Inc.

Insider Sale by Hyep Ivan (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Hyep Ivan, serving as CFO at Bicara Therapeutics Inc. (BCAX), sold 16,518 shares at $18.22 per share, for a total transaction value of $300,971.00. Following this transaction, Hyep Ivan now holds 145,355 shares of BCAX.

This sale represents a 10.00% decrease in Hyep Ivan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 5, 2026, 2 days after the trade was made.

Bicara Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Hyep Ivan

CFO

Ivan Hyep is the Chief Financial Officer (CFO) and Principal Financial and Accounting Officer of Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biotechnology company, a role he has held since March 2021 as part of the founding executive team.[[1]](https://fintool.com/app/research/companies/BCAX/people/ivan-hyep)[[3]](https://www.bicara.com/team/ivan-hyep/)[[8]](https://www.bicara.com/about/) Aged 40 as of April 2025, Hyep holds a BS in Finance from Bentley University and an MBA from Boston University, bringing over 15 years of experience in finance, strategy, and operations.[[1]](https://fintool.com/app/research/companies/BCAX/people/ivan-hyep)[[3]](https://www.bicara.com/team/ivan-hyep/) Prior to Bicara, Hyep served as Director of Finance at MOMA Therapeutics (July 2019–March 2021), where he built the finance function for a pre-IPO biotech; as an Investment Professional at Third Rock Ventures (January 2016–March 2021), focusing on life sciences venture investing; and as Financing Manager at Bain Capital (July 2006–January 2016), developing expertise in structured financing and capital markets.[[1]](https://fintool.com/app/research/companies/BCAX/people/ivan-hyep) Recently, on November 21 and 24, 2025, he sold 18,400 shares of BCAX stock for approximately $341,074 after exercising options, retaining ownership of 145,355 shares valued over $3 million.[[2]](https://www.investing.com/news/insider-trading-news/hyep-ivan-bicara-therapeutics-cfo-sells-341k-in-bcax-stock-93CH-4378618)[[5]](https://www.gurufocus.com/insider/274205/ivan-hyep) Hyep signed the company’s Q3 2025 Sarbanes-Oxley certifications and has received performance-based compensation tied to corporate objectives.[[1]](https://fintool.com/app/research/companies/BCAX/people/ivan-hyep)

View full insider profile →

Trade Price

$18.22

Quantity

16,518

Total Value

$300,971.00

Shares Owned

145,355

Trade Date

Tuesday, March 3, 2026

3 days ago

SEC Filing Date

Thursday, March 5, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Bicara Therapeutics Inc.

Company Overview

No company information available
View news mentioning BCAX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4527553

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime